An Open, Non-Randomised, Crossover Study to Investigate the Effect of AZD9056 (50 mg Oral Dose for 5 Days) on Cytochrome P450 3A Using the Probe Drug Midazolam (7.5 mg Oral and 1 mg Intravenous Dose) in Healthy Patients
Study identifier:D1520C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open, Non-Randomised, Crossover Study to Investigate the Effect of AZD9056 (50 mg Oral Dose for 5 Days) on Cytochrome P450 3A Using the Probe Drug Midazolam (7.5 mg Oral and 1 mg Intravenous Dose) in Healthy Patients
Medical condition
Rheumatoid Arthritis
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
